Evidence map›Paper›PMID 38433277›Full record

ArticleScientific reports2024

Pan-cancer and multi-omics analyses revealed the diagnostic and prognostic value of BAZ2A in liver cancer.

Yan Liu, Junli Wang, Jimin Guo, Qianyi Zhang, Shuqing Wang, Fen Hu, Jinghua Wu, Yating Zhao, Jinghua Zhang, Yuan Yu and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Yan LiuCollege of Life Science, North China University of Science and Technology, Tangshan, 063210, China.
Junli WangCollege of Life Science, North China University of Science and Technology, Tangshan, 063210, China.
Jimin GuoCollege of Life Science, North China University of Science and Technology, Tangshan, 063210, China.
Qianyi ZhangCollege of Life Science, North China University of Science and Technology, Tangshan, 063210, China.
Shuqing WangSchool of Public Health, North China University of Science and Technology, Tangshan, 063210, China.
Fen HuCollege of Life Science, North China University of Science and Technology, Tangshan, 063210, China.
Jinghua WuDepartment of Clinical Laboratory, North China University of Science and Technology Affiliated Tangshan Maternal and Child Health Hospital, Tangshan, 063000, China.
Yating ZhaoDepartment of Breast Center, North China University of Science and Technology Affiliated Hospital, Tangshan, 063210, China.
Jinghua ZhangHebei Key Laboratory of Molecular Oncology, Tangshan, 063001, China. jhzhang_te@163.com.
Yuan YuCollege of Life Science, North China University of Science and Technology, Tangshan, 063210, China. yuyuan5188@163.com.
Yufeng LiHebei Key Laboratory of Molecular Oncology, Tangshan, 063001, China. liyuf56@163.com.
Xiaojun ZhangDepartment of Oncology, People's Hospital of Zunhua, Tangshan, 064200, China. zhangxj869@163.com.
North China University of Science and Technology · CNNorth China University of Science and Technology Affiliated Hospital · CNTangshan People's Hospital · CN

Funding

Hebei Key Laboratory of Molecular Oncology SZX2020043Hebei Provincial Health Commission medical science research project 20240578Innovation Research Team (in Science and Technology) of Tangshan 20130202DNational Natural Science Foundation of China 82173065Natural Science Foundation of Hebei Province H2019105034the project of High level group for research and innovation of School of Public Health, North China University of Science and Technology KYTD202311
6 · The paper itself

Abstract

BAZ2A, an epigenetic regulatory factor that affects ribosomal RNA transcription, has been shown to be highly expressed in several cancers and promotes tumor cell migration. This study explored the expression and mechanism of BAZ2A in tumorigenesis at the pan-cancer level. The Cancer Genome Atlas, Gene Expression Omnibus databases and TIMER2.0, cBioPortal and other tools were used to analyze the level of expression of BAZ2A in various tumor tissues and to examine the relationship between BAZ2A and survival, prognosis, mutation and immune invasion. In vitro experiments were performed to assess the function of BAZ2A in cancer cells. Using combined transcriptome and proteome analysis, we examined the possible mechanism of BAZ2A in tumors. BAZ2A exhibited high expression levels in multiple tumor tissues and displayed a significant association with cancer patient prognosis. The main type of BAZ2A genetic variation in cancer is gene mutation. Downregulation of BAZ2A inhibited proliferation, migration, and invasion and promoted apoptosis in LM6 liver cancer cell. The mechanism of BAZ2A in cancer development may involve lipid metabolism. These results help expand our understanding of BAZ2A in tumorigenesis and development and suggest BAZ2A may serve as a prognostic and diagnostic factor in several cancers.

Indexed as

Liver NeoplasmsMultiomicsBromodomain Containing ProteinsCarcinogenesisCell Transformation, NeoplasticChromosomal Proteins, Non-HistoneHumansPrognosisBAZ2A protein, humanBromodomain Containing ProteinsChromosomal Proteins, Non-HistoneBAZ2AEnrichment analysisLIHCPan-cancerPrognosis

Identifiers

PMID38433277
PMCPMC10909891
OpenAlexW4392401989

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.